The COVID-19 pandemic has put considerable strain on the healthcare services across the globe and is impacting clinical development across many therapeutic areas, as many resources are being diverted to fighting the pandemic.
The Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) Prognostic and Natural History Study (PNHS) aims at understanding the role of amyloid imaging in the earliest stages of Alzheimer’s disease. AMYPAD PNHS adds (semi-)quantitative amyloid PET imaging to several European parent cohorts to predict AD-related progression as well as address methodological challenges in amyloid PET.
On the performance of manually or automatically segmented DATSCAN-SPECT for biomarker extraction in PD
Sleep-Wake Estimation From Actigraphy Data in Parkinson’s Disease: A Deep Learning Approach
IXICO has been featured in S&P Global Market Intelligence's recently published article focused on use of AI technology in drug development. The article entitled 'Big Pharma recruits NASA scientist, sets up command centers in AI push' by Etain Lavelle was originally published here.
IXICO's Associate Director of Technology, Katherine Gray was featured in AMYPAD's recent newsletter to highlight the work she and others within IXICO's tech & data management teams are doing to support AMYPAD projects, using our TrialTracker platform to improve the quality of imaging data.
Fully-automatic AI segmentation of subcortical regions: comparison of ATLAS and deep-learning based approaches
65-72 of 142 results